InvestorsHub Logo
Followers 467
Posts 26918
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 47

Monday, 06/03/2013 9:39:11 AM

Monday, June 03, 2013 9:39:11 AM

Post# of 114
1:33AM Myriad Genetics announces AstraZeneca (AZN) advances PARP inhibitor into Phase 3 Trial With BRACAnalysis (MYGN) 32.10 : Myriad Genetics announces that AstraZeneca (AZN) will use Myriad's BRACAnalysis test as a companion diagnostic to stratify patients in AstraZeneca's pivotal Phase 3 clinical studies for olaparib. Myriad has submitted an Investigational Device Exemption with the FDA for BRACAnalysis testing, which will allow the test to be used as a companion diagnostic to identify potential responders to olaparib therapy in the United States.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MYGN News